Prognostic value of [18F]FDG-PET prior to [131I]MIBG treatment for pheochromocytoma and paraganglioma (PPGL)

[1] Mete O(2022)Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas Endocr Pathol 33 90-114

[2] Asa SL(2015)Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: A single institution experience J Surg Oncol 112 815-821

[3] Gill AJ(2015)Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes J Surg Oncol 112 486-491

[4] Kimura N(2020)Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 31 1476-1490

[5] de Krijger RR(2014)(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis Clin Endocrinol (Oxf) 80 487-501

[6] Tischler A(2007)Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma J Clin Oncol 25 2262-2269

[7] Choi YM(2012)Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography J Natl Cancer Inst 104 700-708

[8] Sung T-Y(2011)Clinical significance of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography for the assessment of 131I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma Eur J Nucl Med Mol Imaging 38 1869-1875

[9] Kim WG(2021)Development and validation of a prediction model based on the organ-based metabolic tumor volume on FDG-PET in patients with differentiated thyroid carcinoma Ann Nucl Med 35 1223-1231

[10] Lee JJ(2013)Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma Oral Oncol. 49 261-268

[1] Mete O(2022)Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas Endocr Pathol 33 90-114

[2] Asa SL(2015)Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: A single institution experience J Surg Oncol 112 815-821

[3] Gill AJ(2015)Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes J Surg Oncol 112 486-491

[4] Kimura N(2020)Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 31 1476-1490

[5] de Krijger RR(2014)(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis Clin Endocrinol (Oxf) 80 487-501

[6] Tischler A(2007)Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma J Clin Oncol 25 2262-2269

[7] Choi YM(2012)Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography J Natl Cancer Inst 104 700-708

[8] Sung T-Y(2011)Clinical significance of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography for the assessment of 131I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma Eur J Nucl Med Mol Imaging 38 1869-1875

[9] Kim WG(2021)Development and validation of a prediction model based on the organ-based metabolic tumor volume on FDG-PET in patients with differentiated thyroid carcinoma Ann Nucl Med 35 1223-1231

[10] Lee JJ(2013)Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma Oral Oncol. 49 261-268